Skip to main
ONC
ONC logo

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines ended 2024 with a robust cash position of US$2.6 billion, indicating strong financial health and operational flexibility for future growth initiatives. The company's leading drug, Brukinsa, experienced a remarkable 105% year-on-year sales increase, achieving US$2.6 billion and reinforcing its dominant position in the blood cancer treatment market, as evidenced by overtaking rival Calquence in both revenue and market share. Additionally, BeOne's other oncology product, Tevimbra, showed a solid 16% year-on-year sales growth to US$621 million, further contributing to a favorable revenue forecast and demonstrating the effectiveness of its strategic market approach.

Bears say

BeiGene's financial outlook appears negative due to a significant decrease in cash flow from operations, which fell from US$188 million in the third quarter to US$75 million in the fourth quarter, driven by higher receivables and inventory accumulation. The company also reported a net loss of US$645 million, marking a 27% year-over-year narrowing, yet this remains concerning given the scale of losses and the potential adverse impact on liquidity. Furthermore, revised estimates for revenue in mature markets have been lowered, with peak sales projections for key drugs like Tevimbra and ociperlimab significantly cut, indicating ongoing challenges in maintaining market share and revenue growth.

BeiGene Ltd (ONC) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 3 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $320.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $320.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.